Dutch biotech developing antibody treatments for autoimmune diseases (CALY-002).
| Date | Round | Amount |
|---|---|---|
| Jan 2024 | Acquired by Novartis Novartis agreed to acquire Dutch autoimmune biotech Calypso Biotech for $250m upfront plus up to $175m in milestone payments, gaining full rights to CALY-002. | $250M |
| Sep 2021 | Series A Dutch biotech Calypso Biotech closed an $8m extension to its Series A, bringing the round to $28m, with Fountain Healthcare Partners joining Gilde Healthcare, Inkef Capital, J&J Innovation and M Ventures, to advance its coeliac-disease antibody CALY-002. | $28M |